Vasculotide (TFA)

O=C(CCN1C(CC(SC[C@@H](C(N[C@@H](CC2=CN=CN2)C(N[C@H](CC3=CN=CN3)C(N[C@@H](CC4=CN=CN4)C(N[C@H](CCCNC(N)=N)C(N[C@@H](CC5=CN=CN5)C(N[C@H](CO)C(N[C@H](C(O)=O)CC6=CC=CC=C6)=O)=O)=O)=O)=O)=O)=O)N)C1=O)=O)NCCOCCOCC(COCCOCCNC(CCN7C(C(SC[C@@H](C(N[C@@H](CC8=CN=CN8)C(N[C@H](CC9=CN=CN9)C(N[C@@H](CC%10=CN=CN%10)C(N[C@H](CCCNC(N)=N)C(N[C@@H](CC%11=CN=CN%11)C(N[C@H](CO)C(N[C@H](C(O)=O)CC%12=CC=CC=C%12)=O)=O)=O)=O)=O)=O)=O)N)CC7=O)=O)=O)(COCCOCCNC(CCN%13C(C(SC[C@H](N)C(N[C@@H](CC%14=CN=CN%14)C(N[C@H](CC%15=CN=CN%15)C(N[C@@H](CC%16=CN=CN%16)C(N[C@H](CCCNC(N)=N)C(N[C@@H](CC%17=CN=CN%17)C(N[C@H](CO)C(N[C@H](C(O)=O)CC%18=CC=CC=C%18)=O)=O)=O)=O)=O)=O)=O)CC%13=O)=O)=O)COCCOCCNC(CCN%19C(C(SC[C@H](N)C(N[C@@H](CC%20=CN=CN%20)C(N[C@H](CC%21=CN=CN%21)C(N[C@@H](CC%22=CN=CN%22)C(N[C@H](CCCNC(N)=N)C(N[C@@H](CC%23=CN=CN%23)C(N[C@H](CO)C(N[C@H](C(O)=O)CC%24=CC=CC=C%24)=O)=O)=O)=O)=O)=O)=O)CC%19=O)=O)=O.O=C(O)C(F)(F)F.[n].[n].[n].[n].[x]

[1]David S, et al. Effects of a synthetic PEG-ylated Tie-2 agonist peptide on endotoxemic lung injury and mortality. Am J Physiol Lung Cell Mol Physiol. 2011 Jun;300 (6) :L851-62.|[2]Kumpers P, et al. The synthetic tie2 agonist peptide vasculotide protects against vascular leakage and reduces mortality in murine abdominal sepsis. Crit Care. 2011;15 (5) :R261.|[3]Trieu M, et al. Vasculotide, an Angiopoietin-1 Mimetic, Restores Microcirculatory Perfusion and Microvascular Leakage and Decreases Fluid Resuscitation Requirements in Hemorrhagic Shock. Anesthesiology. 2018 Feb;128 (2) :361-374.